These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 24849690)

  • 1. A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes.
    Elmore LK; Baggett S; Kyle JA; Skelley JW
    Consult Pharm; 2014; 29(5):335-46. PubMed ID: 24849690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.
    Ji L; Han P; Liu Y; Yang G; Dieu Van NK; Vijapurkar U; Qiu R; Meininger G
    Diabetes Obes Metab; 2015 Jan; 17(1):23-31. PubMed ID: 25175734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
    Bode B; Stenlöf K; Harris S; Sullivan D; Fung A; Usiskin K; Meininger G
    Diabetes Obes Metab; 2015 Mar; 17(3):294-303. PubMed ID: 25495720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
    Stenlöf K; Cefalu WT; Kim KA; Jodar E; Alba M; Edwards R; Tong C; Canovatchel W; Meininger G
    Curr Med Res Opin; 2014 Feb; 30(2):163-75. PubMed ID: 24073995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
    Bode B; Stenlöf K; Sullivan D; Fung A; Usiskin K
    Hosp Pract (1995); 2013 Apr; 41(2):72-84. PubMed ID: 23680739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin.
    Bailey RA; Damaraju CV; Martin SC; Meininger GE; Rupnow MF; Blonde L
    Am J Manag Care; 2014 Jan; 20(1 Suppl):s16-24. PubMed ID: 24512193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
    Usiskin K; Kline I; Fung A; Mayer C; Meininger G
    Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
    Whalen K; Miller S; Onge ES
    Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
    Yale JF; Bakris G; Cariou B; Yue D; David-Neto E; Xi L; Figueroa K; Wajs E; Usiskin K; Meininger G
    Diabetes Obes Metab; 2013 May; 15(5):463-73. PubMed ID: 23464594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.
    Yamout H; Perkovic V; Davies M; Woo V; de Zeeuw D; Mayer C; Vijapurkar U; Kline I; Usiskin K; Meininger G; Bakris G
    Am J Nephrol; 2014; 40(1):64-74. PubMed ID: 25059406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes.
    Nisly SA; Kolanczyk DM; Walton AM
    Am J Health Syst Pharm; 2013 Feb; 70(4):311-9. PubMed ID: 23370138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis.
    Yang XP; Lai D; Zhong XY; Shen HP; Huang YL
    Eur J Clin Pharmacol; 2014 Oct; 70(10):1149-58. PubMed ID: 25124541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
    Stenlöf K; Cefalu WT; Kim KA; Alba M; Usiskin K; Tong C; Canovatchel W; Meininger G
    Diabetes Obes Metab; 2013 Apr; 15(4):372-82. PubMed ID: 23279307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
    Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
    Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus.
    Lamos EM; Younk LM; Davis SN
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):763-75. PubMed ID: 23590413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canagliflozin: a novel treatment option for type 2 diabetes.
    Dietrich E; Powell J; Taylor JR
    Drug Des Devel Ther; 2013; 7():1399-408. PubMed ID: 24285921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
    Forst T; Guthrie R; Goldenberg R; Yee J; Vijapurkar U; Meininger G; Stein P
    Diabetes Obes Metab; 2014 May; 16(5):467-77. PubMed ID: 24528605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes.
    Nigro SC; Riche DM; Pheng M; Baker WL
    Ann Pharmacother; 2013 Oct; 47(10):1301-11. PubMed ID: 24259694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
    Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
    Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.